gemcitabine
Showing 1 - 25 of 3,247
Urinary Bladder Cancer Trial in Assiut (Carboplatin-Gemcitabine Cisplatin-Gemcitabine)
Recruiting
- Urinary Bladder Cancer
- Carboplatin-Gemcitabine Cisplatin-Gemcitabine
-
Assiut, EgyptAssiutU
Apr 22, 2023
Pancreatic Cancer Trial in Hangzhou (Canagliflozin and Gemcitabine, Gemcitabine)
Not yet recruiting
- Pancreatic Cancer
- Canagliflozin and Gemcitabine
- Gemcitabine
-
Hangzhou, Zhejiang, ChinaHangzhou first people's Hospital
Jun 11, 2023
Metastatic Pancreatic Cancer, Adenocarcinoma of the Pancreas Trial in Weiden (nab-paclitaxel and gemcitabine, gemcitabine mono
Completed
- Metastatic Pancreatic Cancer
- Adenocarcinoma of the Pancreas
- nab-paclitaxel and gemcitabine
- gemcitabine mono and nab-paclitaxel and gemcitabine
-
Weiden, GermanyKliniken Nordoberpfalz AG, Klinikum Weiden
Nov 21, 2022
Nasopharyngeal Carcinoma Trial in Xi'an (gemcitabine,nimotuzumab, toripalimab, gemcitabine, cisplatin)
Recruiting
- Nasopharyngeal Carcinoma
- gemcitabine,nimotuzumab, toripalimab
- gemcitabine, cisplatin
-
Xi'an, Shaanxi, ChinaDepartment of Radiation Oncology, Xijing Hospital, Fourth Milita
Sep 5, 2023
Pancreatic Cancer Trial in Baltimore (Gemcitabine, Cisplatin, Pembrolizumab)
Not yet recruiting
- Pancreatic Cancer
- Gemcitabine
- +2 more
-
Baltimore, MarylandSKCCC Johns Hopkins
Aug 16, 2023
Ovarian Cancer, Platinum-resistant Ovarian Cancer Trial in Minsk (Gemcitabine, ELENAGEN)
Active, not recruiting
- Ovarian Cancer
- Platinum-resistant Ovarian Cancer
- Gemcitabine
- ELENAGEN
-
Minsk, BelarusMinsk City Clinical Oncology Center
Jul 27, 2023
Biliary Tract Cancer Trial in Worldwide (Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin)
Not yet recruiting
- Biliary Tract Cancer
- Durvalumab
- +7 more
-
Orange, California
- +36 more
Mar 6, 2023
Cholangiocarcinoma Trial in Houston (Pembrolizumab, Gemcitabine, Cisplatin)
Not yet recruiting
- Cholangiocarcinoma
- Pembrolizumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2023
PDAC - Pancreatic Ductal Adenocarcinoma Trial (Combination of sitagliptin+ gemcitabine + nab-paclitaxel)
Not yet recruiting
- PDAC - Pancreatic Ductal Adenocarcinoma
- Combination of sitagliptin+ gemcitabine + nab-paclitaxel
- (no location specified)
Jul 9, 2023
Pancreatic Cancer Trial (TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine,
Not yet recruiting
- Pancreatic Cancer
- TTX-030, nab-paclitaxel and gemcitabine
- +2 more
- (no location specified)
Nov 3, 2023
Hydroxychloroquine, Gemcitabine, Lung Tumors Trial (Hydroxychloroquine Combined With Gemcitabine)
Not yet recruiting
- Hydroxychloroquine
- +2 more
- Hydroxychloroquine Combined With Gemcitabine
- (no location specified)
Dec 3, 2022
Pancreatic Adenocarcinoma Metastatic Trial in Nanjing (Penpulimab, Anlotinib, Nab paclitaxel)
Recruiting
- Pancreatic Adenocarcinoma Metastatic
- Penpulimab
- +3 more
-
Nanjing, Jiangsu, ChinaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University
Sep 18, 2023
Pancreatic Tumors Trial in Shanghai (Utidelone injection in combination with gemcitabine)
Recruiting
- Pancreatic Neoplasms
- Utidelone injection in combination with gemcitabine
-
Shanghai, Shanghai, ChinaShanghai First People's Hospital
Mar 21, 2023
Locally Advanced Cervical Cancer, Gemcitabine, Chemo-radiotherapy Trial in México (Gemcitabine, Cisplatin)
Recruiting
- Locally Advanced Cervical Cancer
- +2 more
- Gemcitabine
- Cisplatin
-
México, Ciudad De México, MexicoNational Cancer Institute of Mexico
Nov 27, 2023
NMIBC Trial in Beijing (RC48-ADC in Combination with gemcitabine)
Recruiting
- NMIBC
- RC48-ADC in Combination with gemcitabine
-
Beijing, Beijing, ChinaPeking University First Hosptital
Jul 10, 2023
Cancer Of Pancreas Trial (Analyze of GemCore status)
Not yet recruiting
- Cancer Of Pancreas
- Analyze of GemCore status
- (no location specified)
Sep 19, 2023
Metastatic Pancreatic Cancer Trial in Washington (Gemcitabine, Nab paclitaxel, Proglumide Dose level 1)
Not yet recruiting
- Metastatic Pancreatic Cancer
- Gemcitabine
- +3 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023
Nasopharyngeal Carcinoma Trial in Hangzhou (Endostar and Envafolimab)
Recruiting
- Nasopharyngeal Carcinoma
- Endostar and Envafolimab
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Sep 24, 2023
Pancreas Cancer, Non-Resectable Pancreas Carcinoma Trial in Aalborg (Gemcitabine, Nab paclitaxel)
Not yet recruiting
- Pancreas Cancer
- Non-Resectable Pancreas Carcinoma
- Gemcitabine
- Nab paclitaxel
-
Aalborg, DenmarkDepartment of Oncology, Aalborg University Hospital
May 1, 2023
HER2 Gene Mutation Trial in Shanghai (Injection of IAH0968+Gemcitabine+Cisplatin, Gemcitabine+Cisplatin)
Recruiting
- HER2 Gene Mutation
- Injection of IAH0968+Gemcitabine+Cisplatin
- Gemcitabine+Cisplatin
-
Shanghai, ChinaFudan University Affiliated Zhongshan Hospital
Aug 7, 2023
Biliary Tract Carcinoma Trial in Beijing (Gemcitabine, S1, Tislelizumab)
Not yet recruiting
- Biliary Tract Carcinoma
- Gemcitabine
- +2 more
-
Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Apr 10, 2023
Pancreatic Cancer Trial in Tianjin (surufatinib + gemcitabine + nab-paclitaxel)
Recruiting
- Pancreatic Cancer
- surufatinib + gemcitabine + nab-paclitaxel
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jun 15, 2023
Advanced Cholangiocarcinoma Trial in Hangzhou (Lenvatinib, tislelizumab, gemcitabine and cisplatin, Gemcitabine and cisplatin)
Not yet recruiting
- Advanced Cholangiocarcinoma
- Lenvatinib, tislelizumab, gemcitabine and cisplatin
- Gemcitabine and cisplatin
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated Hospital, Zhejiang University School of Me
Apr 10, 2023
Metastatic Pancreatic Adenocarcinoma Trial in Shanghai (Ascorbate, Nab paclitaxel, Gemcitabine)
Recruiting
- Metastatic Pancreatic Adenocarcinoma
- Ascorbate
- +2 more
-
Shanghai, Shanghai, ChinaShanghai Cancer Center
Aug 29, 2023
Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer Trial in Madison (Gemcitabine, Cisplatin, Zimberelimab)
Not yet recruiting
- Biliary Tract Carcinoma
- +2 more
- Gemcitabine
- +3 more
-
Madison, WisconsinUniversity of Wisconsin
Sep 15, 2023